Irinotekan Teva

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotekan Teva, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It is used to treat metastatic colorectal cancer in adult patients.

GNH USA supplies Irinotekan Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotecan is a topoisomerase I inhibitor employed in the management of colorectal cancer.

Metastatic colorectal cancer: improves overall survival and disease control in adult patients with advanced disease.

Irinotecan is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require prompt management. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Fatigue: generalized tiredness during treatment.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophils indicating infection. - Severe colitis: life‑threatening inflammation of the colon. - Allergic reactions: rash, bronchospasm, or anaphylaxis. - Hepatic toxicity: elevated liver enzymes or jaundice. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity. - Monitor blood counts: perform regular complete blood counts to detect neutropenia. - Assess liver function: check hepatic enzymes and bilirubin prior to each cycle. - Evaluate bowel status: avoid use in patients with recent bowel obstruction or perforation. - Avoid in known hypersensitivity: discontinue if severe allergic reaction occurs. - Adjust in hepatic impairment: consider dose reduction based on liver function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce irinotecan exposure. - Concurrent myelosuppressive agents: increase risk of severe neutropenia. - UGT1A1 inhibitors (e.g., atazanavir): can raise SN‑38 levels and toxicity.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): may modestly increase exposure. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Other antineoplastic drugs: assess overlapping toxicities such as mucositis or hepatic effects.